Compare PENN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PENN | PHVS |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1994 | 2021 |
| Metric | PENN | PHVS |
|---|---|---|
| Price | $11.85 | $26.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 9 |
| Target Price | $20.50 | ★ $39.44 |
| AVG Volume (30 Days) | ★ 4.4M | 138.4K |
| Earning Date | 02-26-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,823,800,000.00 | N/A |
| Revenue This Year | $7.19 | N/A |
| Revenue Next Year | $3.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.24 | N/A |
| 52 Week Low | $11.66 | $11.51 |
| 52 Week High | $23.08 | $29.80 |
| Indicator | PENN | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 35.66 | 49.00 |
| Support Level | $12.19 | $25.69 |
| Resistance Level | $14.00 | $28.79 |
| Average True Range (ATR) | 0.70 | 1.47 |
| MACD | -0.06 | -0.11 |
| Stochastic Oscillator | 7.85 | 39.61 |
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/iGaming technology and clientele, helping it form a leading digital position.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.